Meanwhile, at Biohaven's 2025 Annual Meeting of Shareholders, directors Vlad Coric, M.D., and Kishan Mehta were re-elected, and Ernst & Young LLP was ratified as the company's independent auditors for the fiscal year. In the realm of analyst ratings, Piper Sandler has maintained an Overweight rating on Biohaven, citing the potential of its diverse pipeline, including the promising IgG degrader platform. Conversely, Morgan Stanley has adjusted its price target for Biohaven from $69 to $63, while maintaining an Overweight rating, primarily due to revised expectations following the company's recent financial disclosures. Bernstein analysts have expressed concern about regulatory uncertainties due to FDA staff cuts, noting Biohaven as vulnerable given its approaching priority review date for troriluzole. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.